FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130547208> ?p ?o ?g. }

• W3130547208 endingPage "61" @default.
• W3130547208 startingPage "PS7" @default.
• W3130547208 abstract "Abstract Background: While data from traditional registries are typically limited to patients treated at study sites, virtual registries can enroll a broader real-world population. Neat-HER is a U.S.-based virtual registry pilot through PicnicHealth that is enrolling patients with HER2+ breast cancer receiving neratinib as extended adjuvant therapy. Methods: Neat-HER evaluates the feasibility of enrolling patients and answering research questions using a novel electronic platform. Eligibility includes receipt of neratinib in the extended adjuvant setting, signed informed consent for medical record retrieval/data abstraction and age &gt;18 years. Patients who do not complete enrollment procedures, are participating in a clinical trial or have metastatic disease are excluded. Patients are recruited through multiple mechanisms including private social media groups, treating clinicians and patients enrolled in the Puma Texting Program. Patient health records for breast cancer-related treatment are collected from time of diagnosis to 1-year post-enrollment in the registry. Research questions focus on patient and tumor characteristics, receipt of therapy (e.g. radiotherapy, adjuvant therapy), neratinib duration, and diarrhea prophylaxis. Results: 22 patients with HER2+ early-stage breast cancer who received neratinib as extended adjuvant therapy have been enrolled in this registry study since December 2018. Median age was 51 years, with 77% of patients self-identifying as white. 73% of patients had hormone receptor-positive (ER/PR) disease and 73% of patients had node-positive disease. Prior HER2-targeted adjuvant therapy regimens were as follows: trastuzumab with paclitaxel (9%); trastuzumab/pertuzumab in combination (91%; all but 1 of whom also received docetaxel). 16 patients (73%) completed 12 months of neratinib treatment; 3 patients (14%) discontinued treatment early; 3 patients (14%) were still ongoing at the time of data cutoff. 6 patients (27%) had dose holds and 3 patients (14%) had a dose reduction during the course of neratinib treatment. 21 patients (95%) had diarrhea prophylaxis discussed prior to the start of neratinib treatment. Conclusions: Neat-HER provides useful information on patient/tumor characteristics and treatment patterns in a real-world cohort receiving extended adjuvant neratinib. Preliminary results show that this pilot virtual registry is a feasible and efficient modality to collect important data on descriptive characteristics and treatment patterns for a patient population derived from real-world practice settings. Validation of this method is needed and could be used to evaluate important trends such as the frequency of neoadjuvant therapy and associated outcomes in a larger population. Citation Format: Hope S Rugo, Gregory A Vidal, Nina Oestreicher, Deepa Lalla, Gillian Hanson, Yi Zhong, Debu Tripathy. The Neat-HER Virtual Registry: Results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-61." @default.
• W3130547208 created "2021-03-01" @default.
• W3130547208 creator A5012218557 @default.
• W3130547208 creator A5023674071 @default.
• W3130547208 creator A5057389610 @default.
• W3130547208 creator A5057745454 @default.
• W3130547208 creator A5072015843 @default.
• W3130547208 creator A5073189857 @default.
• W3130547208 creator A5090188675 @default.
• W3130547208 date "2021-02-15" @default.
• W3130547208 modified "2023-09-27" @default.
• W3130547208 title "Abstract PS7-61: The Neat-HER Virtual Registry: Results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy" @default.
• W3130547208 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps7-61" @default.
• W3130547208 hasPublicationYear "2021" @default.
• W3130547208 type Work @default.
• W3130547208 sameAs 3130547208 @default.
• W3130547208 citedByCount "0" @default.
• W3130547208 crossrefType "journal-article" @default.
• W3130547208 hasAuthorship W3130547208A5012218557 @default.
• W3130547208 hasAuthorship W3130547208A5023674071 @default.
• W3130547208 hasAuthorship W3130547208A5057389610 @default.
• W3130547208 hasAuthorship W3130547208A5057745454 @default.
• W3130547208 hasAuthorship W3130547208A5072015843 @default.
• W3130547208 hasAuthorship W3130547208A5073189857 @default.
• W3130547208 hasAuthorship W3130547208A5090188675 @default.
• W3130547208 hasConcept C121608353 @default.
• W3130547208 hasConcept C126322002 @default.
• W3130547208 hasConcept C143998085 @default.
• W3130547208 hasConcept C195910791 @default.
• W3130547208 hasConcept C2777982462 @default.
• W3130547208 hasConcept C2778527826 @default.
• W3130547208 hasConcept C2779413316 @default.
• W3130547208 hasConcept C2779786085 @default.
• W3130547208 hasConcept C2781164504 @default.
• W3130547208 hasConcept C2908647359 @default.
• W3130547208 hasConcept C530470458 @default.
• W3130547208 hasConcept C71924100 @default.
• W3130547208 hasConcept C99454951 @default.
• W3130547208 hasConceptScore W3130547208C121608353 @default.
• W3130547208 hasConceptScore W3130547208C126322002 @default.
• W3130547208 hasConceptScore W3130547208C143998085 @default.
• W3130547208 hasConceptScore W3130547208C195910791 @default.
• W3130547208 hasConceptScore W3130547208C2777982462 @default.
• W3130547208 hasConceptScore W3130547208C2778527826 @default.
• W3130547208 hasConceptScore W3130547208C2779413316 @default.
• W3130547208 hasConceptScore W3130547208C2779786085 @default.
• W3130547208 hasConceptScore W3130547208C2781164504 @default.
• W3130547208 hasConceptScore W3130547208C2908647359 @default.
• W3130547208 hasConceptScore W3130547208C530470458 @default.
• W3130547208 hasConceptScore W3130547208C71924100 @default.
• W3130547208 hasConceptScore W3130547208C99454951 @default.
• W3130547208 hasIssue "4_Supplement" @default.
• W3130547208 hasLocation W31305472081 @default.
• W3130547208 hasOpenAccess W3130547208 @default.
• W3130547208 hasPrimaryLocation W31305472081 @default.
• W3130547208 hasRelatedWork W2520267916 @default.
• W3130547208 hasRelatedWork W2791044065 @default.
• W3130547208 hasRelatedWork W2899666201 @default.
• W3130547208 hasRelatedWork W2990541650 @default.
• W3130547208 hasRelatedWork W2991146761 @default.
• W3130547208 hasRelatedWork W3165829877 @default.
• W3130547208 hasRelatedWork W3169470965 @default.
• W3130547208 hasRelatedWork W4361274839 @default.
• W3130547208 hasRelatedWork W4368282709 @default.
• W3130547208 hasRelatedWork W4379531079 @default.
• W3130547208 hasVolume "81" @default.
• W3130547208 isParatext "false" @default.
• W3130547208 isRetracted "false" @default.
• W3130547208 magId "3130547208" @default.
• W3130547208 workType "article" @default.